SCHEMBL3734634

SCHEMBL3734634

C=COC(=O)[C@@H](N)CCC(=O)OC=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.32
KMT2A Q03164 2/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
MEN1 O00255 1/20 0.32
CYP2D6 P10635 1/20 0.32
TSHR P16473 1/20 0.32
NFKB1 P19838 1/20 0.32
CYP2C19 P33261 1/20 0.32
SLC1A1 P43005 2/20 0.31
GRM8 O00222 1/20 0.31
GRM6 O15303 1/20 0.31
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
GSR P00390 1/20 0.31
CYP1A2 P05177 1/20 0.31
GRIK1 P39086 1/20 0.31
GRM5 P41594 1/20 0.31
GRIA1 P42261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5089985 0.93 BLM (0.34) BLMKMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL11655301 0.93 BLM (0.34) BLMKMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL435289 0.91 SLC1A1 (0.34) BLMKMT2ASLC6A2SLC6A4SLC6A3
Acetic Acid SCHEMBL28783576 0.86 SLC1A1 (0.35) BLMKMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL6588925 0.81 GRM8 (0.52) BLMKMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL6588930 0.81 GRM8 (0.52) BLMKMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL21777206 0.81 GRM8 (0.31) SLC1A1GRM8GRM6GRIN2DGRIN3B
SCHEMBL5053704 0.81 SLC1A1 (0.34) BLMKMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL1373501 0.79 SLC1A1 (0.54) BLMKMT2ASLC1A1GRM8GRM6
SCHEMBL20570145 0.78 LTA4H (0.39) BLMKMT2ASLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2457896-A1 Tripeptides as caspase modulators Idun Pharmaceuticals, Inc. (US) 2012-05-30 EP disclosed
EP-2457895-A1 Tetrapeptide analogs Idun Pharmaceuticals, Inc. (US) 2012-05-30 EP disclosed
US-20100190688-A1 Tetrapeptide analogs IDUN PHARMACEUTICALS, INC. 2010-07-29 US disclosed
EP-1773348-A4 TETRAPEPTIDE ANALOGS IDUN PHARMACEUTICALS INC (US) 2009-05-20 EP disclosed
EP-1773348-A2 TETRAPEPTIDE ANALOGS Idun Pharmaceuticals, Inc. (US) 2007-04-18 EP disclosed
WO-2006017295-A2 TETRAPEPTIDE ANALOGS IDUN PHARMACEUTICALS, INC. (US) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190688-A1 Tetrapeptide analogs TP53, PCNA, HRAS BLM 107/4885KMT2A 3553/4885SLC6A2 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.